Dr. Sandor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
ArrayBiopharma
Cambridge, MA 02140
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
McGill University Faculty of MedicineClass of 1990
Certifications & Licensure
VA State Medical License 2000 - 2026
Publications & Presentations
PubMed
- 130 citationsA phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyureaSrdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Peter Rosen
Cancer. 2014-02-15 - 1456 citationsA Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisSrdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta
The New England Journal of Medicine. 2012-03-01 - 358 citationsInhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case reportRichard Piekarz, Rob Robey, Victor Sandor, Susan Bakke, Wyndham H. Wilson
Blood. 2001-11-01
Press Mentions
ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business HighlightsAugust 18th, 2020
ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of DirectorsApril 27th, 2020
ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of DirectorsApril 27th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
